Biopharma sales trended upward in the first quarter of this year as eight of the industry’s top-25 companies achieved double-digit year-over-year growth, which was an uptick from a year ago. | Biopharma sales trended upward in the first quarter of this year as eight of the industry’s top-25 companies achieved double-digit year-over-year growth. It was an uptick from 2025 when there were six drugmakers that had double-digit increases in each of the four quarters.

Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence,

Biopharma sales trended upward in the first quarter of this year as eight of the industry’s top-25 companies achieved double-digit year-over-year growth, which was an uptick from…

With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California biotech appears set up to gain a label expansion for…

Healthcare agencies remain at the forefront of pharmaceutical marketing, but new technologies and shifting political dynamics are putting more pressure on the industry. |…

AbbVie and GSK have surged up the rankings of the pharma companies with the best reputations among U.K. patient groups, contributing to turnover at the top of the leaderboards. |…